tradingkey.logo

tradingkey.logo
āļ„āđ‰āļ™āļŦāļē


Acrivon Therapeutics Inc

ACRV
āđ€āļžāļīāđˆāļĄāļĨāļ‡āđƒāļ™āļĢāļēāļĒāļāļēāļĢāļ•āļīāļ”āļ•āļēāļĄ
1.450USD
-0.010-0.68%
āļ›āļīāļ” 11-13 16:00ET
62.13MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM

āđ€āļāļĩāđˆāļĒāļ§āļāļąāļš Acrivon Therapeutics Inc āļšāļĢāļīāļĐāļąāļ—

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Acrivon Therapeutics Inc āđ‚āļ›āļĢāđ„āļŸāļĨāđŒ


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™ACRV
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Acrivon Therapeutics Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļNov 15, 2022
āļ‹āļĩāļ­āļĩāđ‚āļ­Blume-Jensen (Peter)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™75
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Nov 15
āļ—āļĩāđˆāļ­āļĒāļđāđˆ480 Arsenal Way, Suite 100
āđ€āļĄāļ·āļ­āļ‡WATERTOWN
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ02472
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ16172078979
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://acrivon.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™ACRV
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļNov 15, 2022
āļ‹āļĩāļ­āļĩāđ‚āļ­Blume-Jensen (Peter)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Acrivon Therapeutics Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.05M
-0.77%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
314.13K
-0.65%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
140.09K
-0.43%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
52.59K
-0.76%
Dr. Mansoor Raza Mirza, M.D.
Dr. Mansoor Raza Mirza, M.D.
Chief Medical Officer
Chief Medical Officer
38.82K
--
Dr. Derek DiRocco, Ph.D.
Dr. Derek DiRocco, Ph.D.
Independent Director
Independent Director
9.37K
--
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director
Independent Director
9.37K
--
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
9.37K
--
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
9.37K
--
Dr. Charles M. Baum, M.D., Ph.D.
Dr. Charles M. Baum, M.D., Ph.D.
Independent Director
Independent Director
9.37K
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Dr. Peter Blume-Jensen, M.D., Ph.D.
Dr. Peter Blume-Jensen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.05M
-0.77%
Dr. Kristina Masson, Ph.D.
Dr. Kristina Masson, Ph.D.
Executive Vice President - Business Operations, Director
Executive Vice President - Business Operations, Director
314.13K
-0.65%
Dr. Eric Devroe, Ph.D.
Dr. Eric Devroe, Ph.D.
Chief Operating Officer
Chief Operating Officer
140.09K
-0.43%
Dr. Erick Gamelin, M.D., Ph.D.
Dr. Erick Gamelin, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
52.59K
-0.76%
Dr. Mansoor Raza Mirza, M.D.
Dr. Mansoor Raza Mirza, M.D.
Chief Medical Officer
Chief Medical Officer
38.82K
--
Dr. Derek DiRocco, Ph.D.
Dr. Derek DiRocco, Ph.D.
Independent Director
Independent Director
9.37K
--

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āđƒāļ„āļĢāļ„āļ·āļ­āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Acrivon Therapeutics Inc?


āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Acrivon Therapeutics Inc āđ„āļ”āđ‰āđāļāđˆ: Dr. Peter Blume-Jensen, M.D., Ph.D.

āļĄāļĩāļāļĩāđˆāļŠāļ–āļēāļšāļąāļ™āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Acrivon Therapeutics Inc (ACRV)?


āļ“ āļ§āļąāļ™āļ—āļĩāđˆ 2026Q1 āļĄāļĩāļŠāļ–āļēāļšāļąāļ™āļˆāļģāļ™āļ§āļ™ 141 āđāļŦāđˆāļ‡āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Acrivon Therapeutics Inc āđ‚āļ”āļĒāļĄāļĩāļĄāļđāļĨāļ„āđˆāļēāļĢāļ§āļĄāļ›āļĢāļ°āļĄāļēāļ“ 18.50M āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 45.25% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ” āđ€āļĄāļ·āđˆāļ­āđ€āļ—āļĩāļĒāļšāļāļąāļšāļ§āļąāļ™āļ—āļĩāđˆ 2025Q4 āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™āđ„āļ”āđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™ -3289055.00
tradingkey.logo
āļ„āļģāđ€āļ•āļ·āļ­āļ™āļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡: āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāđāļĨāļ°āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­āļ‚āļ­āļ‡āđ€āļĢāļēāđƒāļŦāđ‰āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļąāđˆāļ§āđ„āļ›āđ€āļāļĩāđˆāļĒāļ§āļāļąāļšāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļšāļēāļ‡āļ›āļĢāļ°āđ€āļ āļ—āđ€āļ—āđˆāļēāļ™āļąāđ‰āļ™ Finsights āđ„āļĄāđˆāđ„āļ”āđ‰āđƒāļŦāđ‰āļ„āļģāđāļ™āļ°āļ™āļģāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļŦāļĢāļ·āļ­āļāļēāļĢāđāļ™āļ°āļ™āļģāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āđƒāļ” āđ† āđāļĨāļ°āļāļēāļĢāđƒāļŦāđ‰āļ‚āđ‰āļ­āļĄāļđāļĨāļ”āļąāļ‡āļāļĨāđˆāļēāļ§āđ„āļĄāđˆāļ„āļ§āļĢāļ–āļđāļāļ•āļĩāļ„āļ§āļēāļĄāļ§āđˆāļēāđ€āļ›āđ‡āļ™āļāļēāļĢāđƒāļŦāđ‰āļ„āļģāđāļ™āļ°āļ™āļģāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļŦāļĢāļ·āļ­āļāļēāļĢāđāļ™āļ°āļ™āļģāđ‚āļ”āļĒ Finsights
āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡āļ”āđ‰āļēāļ™āļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļ­āļĒāđˆāļēāļ‡āļĄāļēāļ āļĢāļ§āļĄāļ–āļķāļ‡āļāļēāļĢāļŠāļđāļāđ€āļŠāļĩāļĒāđ€āļ‡āļīāļ™āļ•āđ‰āļ™āļ—āļĩāđˆāļĨāļ‡āļ—āļļāļ™āđ„āļ› āđāļĨāļ°āļ­āļēāļˆāđ„āļĄāđˆāđ€āļŦāļĄāļēāļ°āļŠāļģāļŦāļĢāļąāļšāļ—āļļāļāļ„āļ™ āļœāļĨāļāļēāļĢāļ”āļģāđ€āļ™āļīāļ™āļ‡āļēāļ™āđƒāļ™āļ­āļ”āļĩāļ•āļ‚āļ­āļ‡āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āđ„āļĄāđˆāđ„āļ”āđ‰āļšāđˆāļ‡āļšāļ­āļāļ–āļķāļ‡āļœāļĨāļāļēāļĢāļ”āļģāđ€āļ™āļīāļ™āļ‡āļēāļ™āđƒāļ™āļ­āļ™āļēāļ„āļ•
Finsights āļ­āļēāļˆāļ­āļ™āļļāļāļēāļ•āđƒāļŦāđ‰āļœāļđāđ‰āļĨāļ‡āđ‚āļ†āļĐāļ“āļēāļŦāļĢāļ·āļ­āļžāļąāļ™āļ˜āļĄāļīāļ•āļĢāļšāļļāļ„āļ„āļĨāļ—āļĩāđˆāļŠāļēāļĄāļ§āļēāļ‡āļŦāļĢāļ·āļ­āļŠāđˆāļ‡āđ‚āļ†āļĐāļ“āļēāļšāļ™āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāļŦāļĢāļ·āļ­āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­āļ‚āļ­āļ‡āđ€āļĢāļēāļŦāļĢāļ·āļ­āļŠāđˆāļ§āļ™āđƒāļ”āļŠāđˆāļ§āļ™āļŦāļ™āļķāđˆāļ‡āļ‚āļ­āļ‡āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāļŦāļĢāļ·āļ­āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­ āđāļĨāļ°āļ­āļēāļˆāđ„āļ”āđ‰āļĢāļąāļšāļ„āđˆāļēāļ•āļ­āļšāđāļ—āļ™āļˆāļēāļāļāļēāļĢāļ—āļĩāđˆāļ„āļļāļ“āļĄāļĩāļ›āļāļīāļŠāļąāļĄāļžāļąāļ™āļ˜āđŒāļāļąāļšāđ‚āļ†āļĐāļ“āļē
ÂĐ āļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒ: FINSIGHTS MEDIA PTE. LTD. āļŠāļ‡āļ§āļ™āļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒāļ—āļļāļāļ›āļĢāļ°āļāļēāļĢ